Key points are not available for this paper at this time.
These consensus-based guidelines can be utilized by clinicians to guide the prevention and management of nausea and vomiting in patients treated with zolbetuximab plus chemotherapy so that patients can continue receiving treatment and achieve benefits.
Klempner et al. (Sat,) studied this question.